EUCTR2014-003563-38-HU进行中（未招募）1 期
A Multicenter Single-arm Extension Study to Characterize the Long-termSafety of Cinacalcet Hydrochloride in the Treatment of SecondaryHyperparathyroidism in Pediatric Subjects With Chronic Kidney Disease onDialysis
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Amgen, Ltd
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •101 Subject’s legally acceptable representative has provided informed consent when the subject is legally too young to provide informed consent and the subject has provided written assent based on local regulations and/or guidelines prior to any day 1 study-specific activities/procedures being initiated.
- •102 Dialysate calcium concentration = 2.5 mEq/L at day 1
- •All subjects from 20130356:
- •103 Completed treatment through week 20 in the 20130356 study
- •104 Dry weight = 12.5 kg at day 1 of Study 20140159
- •Subjects Randomized to the 20130356 Standard of Care Arm Only
- •105 iPTH value = 300 pg/mL (week 19 in 20130356)
- •106 Corrected calcium value = 8.8 mg/dL (week 19 in 20130356)
- •All Subjects from 20110100
- •107 Completed Week 26 End of Study visit in the 20110100 study
- •108 Dry weight = 7 kg at day 1 of Study 20140159
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 78
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Studies 20130356 or 20110100
- •201 Currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(s), other than Amgen Studies 20130356 or 20110100.
- •202 Other investigational procedures while participating in this study are excluded.
- •203 Malignancy except non-melanoma skin cancers, cervical or breast ductal carcinoma in situ within the last 5 years.
- •204 Subject has known sensitivity to any of the products to be administered during dosing.
- •205 Subject likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures (eg, electronic patient diary [ediary]) to the best of the subject and investigator’s knowledge
- •206 History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion.
- •207 Subject previously has entered this study.
- •208 If sexually active, subject is not willing to use highly effective contraception during treatment and for at least 9 days after the end of treatment
- •209 Subject is pregnant or breast feeding, or planning to become pregnant during the study or within 9 days after the end of treatment
- •210 History of congenital long QT syndrome, second or third degree heart block, ventricular tachyarrythmias, or other conditions associated with prolonged QT interval
- •At Day 1 Study Visit-All Subjects:
- •211 Subject has an ongoing adverse event from Studies 20130356 or 20110100 that is considered related to IP and:
- •Is = CTCAE (v 4.0) grade 3, and/or
- •Considered clinically significant in the opinion of the investigator
- •212 Central laboratory values (cCa, iPTH) were not obtained/are not available for
- •20130356 week 19 or
- •20140159 Screening visit for subjects from 20110100 study
- •213 Corrected QT Interval (QTc) > 500 ms, using Bazett’s formula
- •214 QTc = 450 to = 500 ms, using Bazett’s formula, unless written permission toenroll is provided by the investigator after consultation with a paediatric cardiologist
- •215 Use of grapefruit juice, herbal medications, CYP3A4 inhibitors (eg, erythromycin, clarithromycin, ketoconazole, itraconazole), or CYP2D6 substrates (eg, flecainide, propafenone, metoprolol, desipramine, nortriptyline, clomipramine)
- •216 Use of concomitant medications that may prolong the QTc interval
- •(eg, ondansetron, albuterol)
- •At Day 1 Study Visit-Subjects Rolling Over from 20130356 Cinacalcet Arm or from 20110100 Study
- •217 Cinacalcet dose withheld for = last 4 weeks of treatment in studies 20130356 and 201101100.
研究者
相似试验
进行中（未招募）
1 期
A Study to Characterize the Long-term Safety of Cinacalcet Hydrochloride in the Treatment of Secondary Hyperparathyroidism in Children With Chronic Kidney Disease On DialysisEUCTR2014-003563-38-BEAmgen, Inc.48
进行中（未招募）
1 期
A Study to Characterize the Long-term Safety of Cinacalcet Hydrochloride in the Treatment of Secondary Hyperparathyroidism in Children With Chronic Kidney Disease On DialysisSecondary Hyperparathyroidism and Chronic Kidney Disease ReceivingDialysisMedDRA version: 18.0Level: PTClassification code 10020708Term: Hyperparathyroidism secondarySystem Organ Class: 10014698 - Endocrine disordersEUCTR2014-003563-38-FRAmgen, Inc.48
进行中（未招募）
1 期
A Study to Characterize the Long-term Safety of Cinacalcet Hydrochloride in the Treatment of Secondary Hyperparathyroidism in Children With Chronic Kidney Disease On DialysisSecondary Hyperparathyroidism and Chronic Kidney Disease ReceivingDialysisMedDRA version: 19.0Level: PTClassification code 10020708Term: Hyperparathyroidism secondarySystem Organ Class: 10014698 - Endocrine disordersEUCTR2014-003563-38-CZAmgen, Inc.48
进行中（未招募）
1 期
A Study to Characterize the Long-term Safety of Cinacalcet Hydrochloride in the Treatment of Secondary Hyperparathyroidism in Children With Chronic Kidney Disease On DialysisEUCTR2014-003563-38-SKAmgen, Inc.48
进行中（未招募）
1 期
A Study to Characterize the Long-term Safety of Cinacalcet Hydrochloride in the Treatment of Secondary Hyperparathyroidism in Children With Chronic Kidney Disease On DialysisSecondary Hyperparathyroidism and Chronic Kidney Disease Receiving DialysisMedDRA version: 18.0Level: PTClassification code 10020708Term: Hyperparathyroidism secondarySystem Organ Class: 10014698 - Endocrine disordersEUCTR2014-003563-38-ESAmgen, Inc.48